Peer Support & Storytelling for COPD
(ImPReSS-COPD Trial)
Trial Summary
What is the purpose of this trial?
Chronic Obstructive Pulmonary Disease (COPD) affects approximately 16 million Americans and is characterized by recurrent exacerbations that lead to 1.5 million Emergency Department visits and 700,000 hospitalizations annually. Pulmonary rehabilitation (PR) is a structured program of exercise and self-management support that has been proven to relieve shortness of breath and increase quality of life when initiated after an exacerbation, but unfortunately, few eligible patients participate. This project will compare the effectiveness of two novel strategies - one involving video narratives of other patients telling their story of how they overcame challenges and completed PR, the other involving telephonic peer coaching with an individual with lived experience - to enhanced usual care, and to each other, at increasing patient participation in PR after an exacerbation.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on participation in pulmonary rehabilitation and peer support.
What data supports the effectiveness of the treatment Peer Support & Storytelling for COPD?
Research shows that phone-based peer coaching can reduce depressive symptoms and sleep disturbances in COPD patients, and narrative medicine helps improve the doctor-patient relationship, which can lead to better treatment adherence. These components suggest that storytelling and peer support may positively impact COPD management.12345
Is peer support and storytelling safe for use in clinical settings?
Research suggests that peer support and storytelling interventions are generally safe, as they focus on improving communication and engagement without involving medical procedures or drugs. These methods have been used to enhance safety in hospital settings and empower patients to participate in their care.678910
How does the Peer Support & Storytelling treatment for COPD differ from other treatments?
This treatment is unique because it focuses on peer support and storytelling to help manage COPD, rather than relying solely on medication or traditional therapies. It emphasizes the psychosocial aspects of living with COPD, aiming to improve quality of life through shared experiences and emotional support.12111213
Research Team
Peter Lindenauer, MD, MSc
Principal Investigator
Baystate Health
Eligibility Criteria
This trial is for individuals over 40 with COPD who've been treated for an exacerbation and referred to pulmonary rehabilitation (PR). Participants must be willing to engage in peer coaching calls, watch storytelling videos, have a working phone, and communicate in English. Those not eligible or unwilling to attend PR, in hospice care, living in long-term facilities, or who have already completed significant PR are excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
R61 Phase
Recruit and train peer coaches, recruit storytellers, capture narratives on video, finalize protocol, trial infrastructure, and pilot recruitment strategy
R33 Phase
Recruit 305 adults treated for exacerbation of COPD, randomize them to Enhanced Usual Care, eUC + Storytelling, or eUC + Peer Support, and evaluate effectiveness at promoting participation in PR at 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Storytelling (Behavioral Intervention)
- Telephonic Peer Coaching (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baystate Medical Center
Lead Sponsor
Peter Banko
Baystate Medical Center
Chief Executive Officer
MBA from Stanford University
Dr. Yvonne Cheung
Baystate Medical Center
Chief Medical Officer since 2024
MD from Columbia University, MPH from Harvard School of Public Health, MBA from University of Massachusetts Amherst
University of Michigan
Collaborator
Marschall S. Runge
University of Michigan
Chief Executive Officer since 2015
MD, PhD
Karen McConnell
University of Michigan
Chief Medical Officer since 2020
MD
University of Massachusetts, Worcester
Collaborator
Dr. Eric W. Dickson
University of Massachusetts, Worcester
Chief Executive Officer since 2013
MD from UMass Chan Medical School, Master's in Health Care Management from Harvard University
Dr. Andy Karson
University of Massachusetts, Worcester
Chief Medical Officer
MD
COPD Foundation
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Dr. Gary H. Gibbons
National Heart, Lung, and Blood Institute (NHLBI)
Chief Executive Officer since 2012
MD from Harvard Medical School
Dr. James P. Kiley
National Heart, Lung, and Blood Institute (NHLBI)
Chief Medical Officer since 2011
MD from University of California, San Francisco